| Identification | Back Directory | [Name]
MMP-9-IN-1 | [CAS]
502887-71-0 | [Synonyms]
OUN87710
MMP-9-IN-1
Acetamide, N-[4-(difluoromethoxy)phenyl]-2-[(1,6-dihydro-6-oxo-4-propyl-2-pyrimidinyl)thio]- | [Molecular Formula]
C16H17F2N3O3S | [MDL Number]
MFCD09276885 | [MOL File]
502887-71-0.mol | [Molecular Weight]
369.39 |
| Chemical Properties | Back Directory | [density ]
1.37±0.1 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO: 125 mg/mL (338.40 mM) | [form ]
Solid | [pka]
7.80±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which
selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs[1]. | [Definition]
ChEBI: MMP-9-IN-1 is a secondary carboxamide resulting from the formal condensation of the carboxy group of [(4-oxo-6-propyl-1,4-dihydropyrimidin-2-yl)sulfanyl]acetic acid with the amino group of 4-(difluoromethoxy)aniline. It is a specific matrix metalloproteinase-9 (MMP-9) inhibitor. It has a role as an EC 3.4.24.35 (gelatinase B) inhibitor and an antineoplastic agent. It is an organofluorine compound, an aromatic compound, a pyrimidone, an organic sulfide and a secondary carboxamide. | [Biological Activity]
MMP-9-IN-1 (OUN87710) is a specific inhibitor of matrix metalloproteinase-9 (MMP-9). MMP-9-IN-1 selectively targets the heme (PEX) domain of MMP-9 with a Kd of 2.1 μM. | [in vivo]
MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor.
MMP-9-IN-1 inhibits cancer cell metastasis in vivo. | Animal Model: | 4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks, | | Result: | Resulted in a profound delay in tumor growth.
Inhibited cancer cell metastasis. | | [target]
| Target | Value | MMP-9
(Cell-free assay) | 2.1 μM(Kd) |
| [IC 50]
MMP-9 | [storage]
Store at -20°C | [References]
[1] Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88. DOI:10.1158/0008-5472.CAN-10-4552
[2] Alford VM, Kamath A, Ren X, et al. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. ACS Chem Biol. 2017;12(11):2788-2803. DOI:10.1021/acschembio.7b00758 |
|
|